Company news
Denali Therapeutics Inc. (NASDAQ:DNLI) news
Denali Therapeutics Inc. news releases on 6ix. Latest, Aug 6, 2026: Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Press releases & updates
Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
August 6, 2026
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
July 27, 2026
Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier
July 9, 2026
Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
June 18, 2026
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
May 20, 2026
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
May 7, 2026
Orsini Selected as the Exclusive Specialty Pharmacy and Home Infusion Partner for Denali Therapeutics' AVLAYAH™ (tividenofusp alfa-eknm)
April 20, 2026
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
April 2, 2026
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
March 24, 2026
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
February 26, 2026
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
February 5, 2026
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
February 1, 2026
Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™
January 28, 2026
Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome
January 5, 2026
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
December 29, 2025
PLX: Secarna’s Antisense Oligonucleotide Discovery Collaboration
December 22, 2025
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
December 9, 2025
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
December 8, 2025
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
December 3, 2025
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
December 3, 2025
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
November 5, 2025
Denali Therapeutics Announces Board and Executive Leadership Updates
November 5, 2025
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)
October 12, 2025
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
August 10, 2025
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors
July 17, 2025
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
July 6, 2025
Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome
May 5, 2025
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome and Positive Ongoing Interactions with FDA on DNL126 through START Program
April 3, 2025
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program
April 1, 2025
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
February 26, 2025
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
February 5, 2025
Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™
January 29, 2025
Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
January 12, 2025
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
January 7, 2025
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
January 5, 2025
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease
December 4, 2024
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
November 5, 2024
Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)
September 2, 2024
Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following In...
August 13, 2024
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
July 31, 2024
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
June 2, 2024
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
May 6, 2024
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
April 30, 2024
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
February 26, 2024
Denali Therapeutics Announces $500 million Private Placement Equity Financing
February 26, 2024
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
February 6, 2024
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
January 31, 2024
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
January 7, 2024
Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
November 6, 2023
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023
August 29, 2023